.Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01B_PosteriorPituitaryLobeHormones.H01BA04_Terlipressin.Terlipressin .Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01B_PosteriorPituitaryLobeHormones.H01BA04_Terlipressin.Terlipressin| name: | Terlipressin | |
| ATC code: | H01BA04 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 2 | mg |
| volume of distribution: | 0.42 | L |
| clearance: | 9 | mL/min/kg |
| other parameters in model implementation | ||
Terlipressin is a synthetic analog of vasopressin used primarily in the management of bleeding esophageal varices and hepatorenal syndrome in patients with liver cirrhosis. It is a prodrug, slowly metabolized to lysine vasopressin (the active form) and is administered intravenously. Terlipressin is approved and in use in several countries for these indications.
Pharmacokinetic parameters reported for adult patients with bleeding esophageal varices, both male and female, with impaired liver function. Intravenous administration.
Bateman, RM, et al., & Prandi, E (2016). 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016. Critical care (London, England) 20(Suppl 2) 94–None. DOI:10.1186/s13054-016-1208-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27885969